8 recruiting, 5 unknown, 4 terminated, 3 completed. 8 Phase 2, 5 Phase 3, 4 Not applicable, 2 Phase 4.
Follow Janus Kinase Inhibitors: new trials by email Literature Review of Janus Kinase Inhibitors trials Research Report on Janus Kinase Inhibitors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Ruxolitinib in Patients With HNSCC and High NLR Treated With Pembrolizumab - The Phase 2 InflammaSTOP Trial Ruxolitinib, Pembrolizumab - Carcinoma, Squamous Cell of Head and Neck HNSCC | Phase 2 | Not yet recruiting | University Hospital, Basel, Switzerland | 66 | 2026-11-01 | 2026-10-20 |
| A Study on the Efficacy and Safety of JAK Inhibitors Versus Calcineurin Inhibitors as Initial Therapy for Interstitial Lung Disease Associated With Antisynthetase Syndrome JAK Inhibitor, Calcineurin Inhibitors (CNI) - Antisynthetase Syndrome, Interstitial Lung Disease (ILD) | Not applicable | Recruiting | China-Japan Friendship Hospital | 80 | 2026-05-18 | 2026-06-03 |
| Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes Ruxolitinib, Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan - Myelodysplastic/Myeloproliferative Neoplasm, Primary Myelofibrosis | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 50 | 2026-02-04 | 2026-10-19 |
| A Prospective Cohort Study Evaluating the Efficacy and Safety of Guselkumab (GUS) With JAK Inhibitors in Patients With Difficult-To-Treat Inflammatory Bowel Disease (IBD) guselkumab (GUS), JAK inhibitors (such as upadacitinib/tofacitinib) - Inflamatory Bowel Disease | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 80 | 2026-01-07 | 2026-03-23 | |
| Comparison Between JAK Inhibitors and Traditional Treatment of Rheumatoid Arthritis JAK inhibitors and traditional treatment of rheumatoid arthritis - Rheumatoid Arthritis, Arthritis | Not yet recruiting | Assiut University | 72 | 2025-12-20 | 2025-12-09 | |
| JAK Inhibitors for Solid Malignant Tumor Patients With Immune Checkpoint Inhibitors-related Dermatitis: A Open-lable, Single Arm, Phase IIa Trial JAK Inhibitor - Immune Checkpoint Inhibitors (ICI)-Related Dermatitis | Phase 2 | Recruiting | Shixiu Wu | 35 | 2024-12-31 | 2025-10-28 |
| Efficacy and Safety of Tofacitinib in Refractory Blau Syndrome Janus Kinase Inhibitor - Blau Syndrome | Phase 4 | Enrolling by invitation | Peking Union Medical College Hospital | 30 | 2024-10-01 | 2024-10-28 |
| Methotrexate Combined With Tofacitinib in Rheumatoid Arthritis Methotrexate Combined With Tofacitinib, Methotrexate - Rheumatoid Arthritis | Not applicable | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 130 | 2024-09-01 | 2026-05-12 |
| Baricitinib for the Lung Injury Following Spontaneous SAH Baricitinib 4 MG, Standard treatment - Spontaneous Subarachnoid Hemorrhage | Phase 2 | Not yet recruiting | Tang-Du Hospital | 100 | 2024-08-01 | 2024-06-03 |
| Evaluate the Efficacy of Anti-Jak1 Inhibitors as Treatment for Patients With Aicardi-Goutières Syndrome JAK Inhibitor - Aicardi-Goutières Syndrome (AGS) | Completed | IRCCS Fondazione Stella Maris | 24 | 2024-04-07 | 2025-03-27 | |
| The PODIUM Study - a Three-arm Comparison of Target Therapies After Anti-TNFα in Ulcerative Colitis Vedolizumab, Ustekinumab - Standard Dosage, JAK Inhibitor - Ulcerative Colitis (Disorder) | Recruiting | Humanitas Clinical and Research Center | 450 | 2023-08-01 | 2024-11-15 | |
| The Use of Synovial Biopsies in Predicting Response to Biologic Therapy in Rheumatoid Arthritis Patients Anti-TNF, JAK inhibitor - Rheumatoid Arthritis | Phase 3 | Withdrawn | Abu Dhabi Stem Cells Center | 2023-03-01 | 2025-10-06 | |
| Immunoclassification of Psoriasis: a Strategy for Precision Medicine adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors, methotrexate - Immunoclassification, Psoriasis | Not applicable | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 100 | 2023-01-01 | 2024-01-12 |
| Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis Janus Kinase Inhibitor, Abatacept - Abatacept, Treatment Compliance | Phase 3 | Unknown | Zhejiang Provincial People's Hospital | 90 | 2022-09-30 | 2022-09-23 |
| JAK Inhibitors' Efficacy in Bullous Pemphigoid Janus Kinase Inhibitor - Bullous Pemphigoid, Janus Kinase Inhibitor | Completed | Chao Ji | 120 | 2022-01-01 | 2024-09-05 | |
| Baricitinib in Hospitalized Covid-19 Patients With Diabetes Mellitus Baricitinib, Dexamethasone, Remdesivir - COVID-19 Pneumonia | Phase 3 | Withdrawn | Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders | 2021-07-10 | 2024-04-09 | |
| PANLAR's Latin American Registry of Rheumatic Patients Treated With Jak Inhibitors DMARDs, biologic DMARDs, JAK Inhibitor - Arthritis, Rheumatoid, Arthritis, Psoriatic | Unknown | Liga Panamericana de Asociaciones de Reumatologia (PANLAR) | 3000 | 2021-03-01 | 2021-03-29 | |
| Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis Cyclophosphamide, JAK Inhibitor, Fludarabine - Primary Myelofibrosis, Secondary Myelofibrosis | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 20 | 2021-02-09 | 2026-07-20 |
| Predicting the Response of Patients With Rheumatoid Arthritis to Treatment With Genetically Engineered Biological Drugs and Janus (JAK) Kinase Inhibitors genetically engineered biological drugs, Janus-kinase inhibitors, tumor necrosis factor inhibitors - Rheumatoid Arthritis | Completed | Institute of Biomedical Chemistry, Russia | 50 | 2021-01-15 | 2023-12-20 | |
| Effect of Antiinflammatory Treatment Versus Hand Training on Neuropsychiatric Comorbidity in RA-patients TNF-α inhibitor OR JAK inhibitor, Hand training - Rheumatoid Arthritis, Pain | Not applicable | Unknown | Vastra Gotaland Region | 212 | 2020-10-01 | 2022-05-04 |
Showing 20 of 26. Sign in to see all of them.
Arthritis, Rheumatoid (7) · COVID-19 (4) · Colitis, Ulcerative (2) · Pneumonia (2) · Primary Myelofibrosis (2) · Antisynthetase syndrome (1) · Arthritis (1) · Arthritis, Psoriatic (1) · Blau syndrome (1) · Brain Diseases (1) · Carcinoma (1) · Cognitive Dysfunction (1) · Coronavirus Infections (1) · Cytokine Release Syndrome (1) · Depression (1)
Fred Hutchinson Cancer Center (2) · Second Affiliated Hospital, Zhejiang University, School of Medicine (2) · Abu Dhabi Stem Cells Center (1) · Alimentiv Inc. (1) · Assiut University (1) · Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders (1) · CTI BioPharma (1) · Chao Ji (1) · China-Japan Friendship Hospital (1) · First Affiliated Hospital Xi'an Jiaotong University (1) · Humanitas Clinical and Research Center (1) · IRCCS Fondazione Stella Maris (1) · Incyte Corporation (1) · Institute of Biomedical Chemistry, Russia (1) · Liga Panamericana de Asociaciones de Reumatologia (PANLAR) (1)
China (9) · United States (4) · Italy (2) · Russia (2) · Argentina (1) · Bangladesh (1) · Brazil (1) · Canada (1) · Germany (1) · Netherlands (1) · Sweden (1) · Switzerland (1) · United Arab Emirates (1)
Anna Brandt, PD Dr. (1) · Chao Ji, PhD (1) · Gianina Statache, MD (1) · Lan He (1) · Maria Bokarewa, MD (1) · Rachel B. Salit (1) · Rachel Salit, MD (1) · Rene A. Rivero Jimenez, PhD (1) · Vipul Jairath, MD, PhD (1) · Wasim MM Haque, FCPS (1) · Yan Qu, PhD MD (1)
PMID 22263004, PMID 29229575, PMID 30060040, PMID 31314977, PMID 31375890, PMID 32423584, PMID 32445440, PMID 32647915, PMID 32678530, PMID 32800858, PMID 32821939, PMID 33129421, PMID 33264556, PMID 33268335, PMID 33306283, PMID 33760094, PMID 33969237, PMID 33990684, PMID 34133856, PMID 34192610, PMID 36226977, PMID 36469321, PMID 41616901, PMID 42192374